This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.

ConditionMSI-H or dMMR Advanced Solid Tumors

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorShanghai Qilu Pharmaceutical Research and Development Center LTD

About this trial

The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.

Eligibility criteria

Qualifiers

None

Disqualifiers

1. Have a history of allergy to any component of the study drug. 2. Oral medication is not allowed. 3. The residual toxic reactions caused by previous anti-tumor treatment are higher than Grade 1 according to CTCAE v6.0.

Trial design

Treatments tested in this trial

QLS1317

Treatment groups

120 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Shanghai Qilu Pharmaceutical Research and Development Center LTD

Lead sponsor

Source ClinicalTrials.gov